Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatrogon Pen vs Vial Bioequivalence
NCT03810664Phase 1Completed
- Sponsor
- OPKO Health
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of somatrogon in growth hormone deficiency (GHD) (2 arms), sponsored by OPKO Health. Primary endpoints: Area under the curve from time 0 to the last measurable concentration at 30 days, Area under the curve from time 0 to infinity at 30 days and 1 more. Started Jan 2019; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03810664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810664.